Genprex, INC S-1 registration statements

Genprex, a clinical-stage gene therapy company, filed an S-1/A to register 1.28 million shares for resale by selling stockholders, while detailing progress in its oncology and diabetes programs and recent financing activities.

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 1.28 million common shares for resale by selling stockholders, while also providing updates on its oncology and diabetes programs and recent financing activities.

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 25 million common shares for resale by Lincoln Park Capital Fund, LLC, while facing Nasdaq delisting for bid price and equity non-compliance.

Genprex, a clinical-stage gene therapy company, has entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $12.5 million in common stock, while advancing its oncology and diabetes programs and addressing Nasdaq listing requirements.

Genprex aims to raise capital through a public offering of common stock, pre-funded warrants, and accompanying warrants, with proceeds intended for working capital and general corporate purposes.